BioWorld - Wednesday, January 28, 2026

BioWorld Science

Nov. 28, 2016

View Archived Issues

European Commission awards orphan drug designation to SENS-401

Read More

Primary analysis results for phase III trial of tau-aggregation inhibitor therapy

Read More

Aptinyx presents in vitro and in vivo data for its NMDA receptor modulator JY-515317

Read More

Atom Bioscience and Pharmaceutical patents anticancer agents

Read More

Tarveda initiates phase I/IIa study of PEN-221 in SSTR2-expressing advanced cancers

Read More

FDA clears TopiVert's IND for phase I/IIa study of TOP-1630 in dry eye syndrome

Read More

GSK announces MAA submission to the EMA for Shingrix

Read More

Zebrafish model of fatty liver reveals role of 12-lipoxygenase

Read More

Chugai and Berlin-Chemie Menarini sign global license agreement for PA-799

Read More

Intellipharmaceutics submits NDA in U.S. for Rexista

Read More

Johnson & Johnson in preliminary discussions with Actelion

Read More

Ambroxol could be repurposed to treat fibromyalgia

Read More

AbbVie initiates phase I trial of ABBV-428 in advanced solid tumors

Read More

Phase III rheumatoid arthritis study finds equivalence between rituximab and biosimilar CT-P10

Read More

New TRPC4/5 inhibitor shows promise for anxiety and depression

Read More

HVTN initiates phase IIb/III trial of investigational HIV vaccine regimen in South Africa

Read More

Santen announces topline results from SAKURA phase III program of Opsiria

Read More

Data validate SIME Dx's lung maturity test for identifying infants at risk of RDS

Read More

Araim Pharmaceuticals' ARA-290 granted orphan drug designation in E.U.

Read More

Enrollment completed in phase IIa study of Serodus' SER-150

Read More

PharmaMar begins phase I study of lurbinectedin in Japan

Read More

Results mixed with everolimus and low-dose CIs in pediatric liver transplant recipients

Read More